Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11

Vaccine

Volumn 32, Issue 10, 2014, Pages 1205-1212

  Namkoong, Hong ^a   Song, Mi Young ^a   Seo, Yong Bok ^a   Choi, Dong Hoon ^a   Kim, Sae Won ^a   Im, Se Jin ^a   Sung, Young Chul ^a   Park, Yunji ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

Adjuvant; CD8 T cell; CXCL11; Memory; Vaccination

Indexed keywords

ADJUVANT; CD8 T CELL; CXCL11; MEMORY; VACCINATION;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHEMOKINE CXCL10; CHEMOKINE CXCL11; CHEMOKINE CXCL9; CYTOKINES; FEMALE; HEK293 CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS E7 PROTEINS;

EID: 84893903921     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.066     Document Type: Article

References (35)

1. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
2. Groom J.R., Luster A.D. CXCR3 in T cell function. Exp Cell Res 2011, 317:620-631.
3. Dar W.A., Knechtle S.J. CXCR3-mediated T-cell chemotaxis involves ZAP-70 and is regulated by signalling through the T-cell receptor. Immunology 2007, 120:467-485.
4. Newton P., O'Boyle G., Jenkins Y., Ali S., Kirby J.A. T cell extravasation: demonstration of synergy between activation of CXCR3 and the T cell receptor. Mol Immunol 2009, 47:485-492.
5. Kurachi M., Kurachi J., Suenaga F., Tsukui T., Abe J., Ueha S., et al. Chemokine receptor CXCR3 facilitates CD8(+) T cell differentiation into short-lived effector cells leading to memory degeneration. J Exp Med 2011, 208:1605-1620.
6. Kohlmeier J.E., Reiley W.W., Perona-Wright G., Freeman M.L., Yager E.J., Connor L.M., et al. Inflammatory chemokine receptors regulate CD8(+) T cell contraction and memory generation following infection. J Exp Med 2011, 208:1621-1634.
7. Hu J.K., Kagari T., Clingan J.M., Matloubian M. Expression of chemokine receptor CXCR3 on T cells affects the balance between effector and memory CD8 T-cell generation. Proc Natl Acad Sci U S A 2011, 108:E118-E127.
8. Groom J.R., Luster A.D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011, 89:207-215.
9. Farber J.M. Mig and I.P-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997, 61:246-257.
10. Whiting D., Hsieh G., Yun J.J., Banerji A., Yao W., Fishbein M.C., et al. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J Immunol 2004, 172:7417-7424.
11. Rosenblum J.M., Shimoda N., Schenk A.D., Zhang H., Kish D.D., Keslar K., et al. CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors. J Immunol 2010, 184:3450-3460.
12. Yoon H.A., Eo S.K. Differential polarization of immune responses by genetic cotransfer of chemokines changes the protective immunity of DNA vaccine against pseudorabies virus. Immunology 2007, 120:182-191.
13. Krathwohl M.D., Anderson J.L., Chemokine C.X.C. L10 (IP-10) is sufficient to trigger an immune response to injected antigens in a mouse model. Vaccine 2006, 24:2987-2993.
14. Kang T.H., Kim K.W., Bae H.C., Seong S.Y., Kim T.W. Enhancement of DNA vaccine potency by antigen linkage to IFN-gamma-inducible protein-10. Int J Cancer 2011, 128:702-714.
15. Dufour J.H., Dziejman M., Liu M.T., Leung J.H., Lane T.E., Luster A.D. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002, 168:3195-3204.
16. Biragyn A., Tani K., Grimm M.C., Weeks S., Kwak L.W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999, 17:253-258.
17. Kim D.J., Youn J.I., Seo S.H., Jin H.T., Sung Y.C. Differential regulation of antigen-specific CD8+ T cell responses by IL-12p40 in a dose-dependent manner. J Immunol 2008, 180:7167-7174.
18. Nam H.J., Song M.Y., Choi D.H., Yang S.H., Jin H.T., Sung Y.C. Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant. Eur J Immunol 2010, 40:351-358.
19. Jin H.T., Youn J.I., Kim H.J., Lee J.B., Ha S.J., Koh J.S., et al. Enhancement of interleukin-12 gene-based tumor immunotherapy by the reduced secretion of p40 subunit and the combination with farnesyltransferase inhibitor. Hum Gene Ther 2005, 16:328-338.
20. Song M.Y., Park S.H., Nam H.J., Choi D.H., Sung Y.C. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1. J Immunother 2011, 34:297-306.
21. Hikono H., Kohlmeier J.E., Takamura S., Wittmer S.T., Roberts A.D., Woodland D.L. Activation phenotype, rather than central-or effector-memory phenotype, predicts the recall efficacy of memory CD8(+) T cells. J Exp Med 2007, 204:1625-1636.
22. Chowdhury F.Z., Ramos H.J., Davis L.S., Forman J., Farrar J.D. IL-12 selectively programs effector pathways that are stably expressed in human CD8(+) effector memory T cells in vivo. Blood 2011, 118:3890-3900.
23. Dailey M.O., Pillemer E., Weissman I.L. Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone. Proc Natl Acad Sci U S A 1982, 79:5384-5387.
24. Greenberg P.D. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia. J Immunol 1986, 136:1917-1922.
25. Greenberg P.D., Kern D.E., Cheever M.A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 1985, 161:1122-1134.
26. Khan I.A., MacLean J.A., Lee F.S., Casciotti L., DeHaan E., Schwartzman J.D., et al. IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 2000, 12:483-494.
27. Hancock W.W., Gao W., Csizmadia V., Faia K.L., Shemmeri N., Luster A.D. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001, 193:975-980.
28. Colvin R.A., Campanella G.S.V., Sun J.T., Luster A.D. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 2004, 279:30219-30227.
29. Cole K.E., Strick C.A., Paradis T.J., Ogborne K.T., Loetscher M., Gladue R.P., et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998, 187:2009-2021.
30. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009, 15:293-299.
31. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
32. Friedrich T.C., Valentine L.E., Yant L.J., Rakasz E.G., Piaskowski S.M., Furlott J.R., et al. Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J Virol 2007, 81:3465-3476.
33. Mudd P.A., Martins M.A., Ericsen A.J., Tully D.C., Power K.A., Bean A.T., et al. Vaccine-induced CD8(+) T cells control AIDS virus replication. Nature 2012.
34. King C.A., Spellerberg M.B., Zhu D., Rice J., Sahota S.S., Thompsett A.R., et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998, 4:1281-1286.
35. Hakim I., Levy S., Levy R. A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 1996, 157:5503-5511.